Hemorrhagic stroke associated with Prasugrel treatment: a review of the literature
DOI:
https://doi.org/10.56294/ri202537Keywords:
Hemorrhagic Stroke, Prasugrel, Risk Factors, StrokeAbstract
Introduction: patients receiving treatment with Prasugrel for the prevention of acute coronary artery disease may suffer a hemorrhagic stroke as a complication, this being one of the most serious complications and with the highest mortality associated with the use of antiplatelet agents.
Objective: to analyze the relationship between antiplatelet therapy with Prasugrel and the occurrence of hemorrhagic stroke.
Methods: search of information in the Scopus, Web of Science and SciELO databases on hemorrhagic encephalic vascular accidents during the use of Prasugrel.
Results: a total of 50 articles were found that met the inclusion and exclusion criteria, 3 of which were used for this study.
Conclusion: risk factors such as arterial hypertension, diabetes, advanced age predisposes patients to hemorrhagic stroke during treatment with Prasugrel
References
1. Goodman & Gilman. Las bases farmacológicas de la terapéutica. 2023.
2. Bundhun PK, Huang F. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis. BMC Cardiovasc Disord. 2018 May 2;18(1). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932806/
3. American College of Cardiology. Comparison of Clopidogrel and Prasugrel for Prevention of Ischemic Events in Acute Coronary Syndrome. Disponible en: https://www.acc.org/latest-in-cardiology/articles/2017/06/22/06/24/comparison-of-clopidogrel-and-prasugrel-for-prevention-of-ischemic-events-in-acs
4. De Jaén U, Alumno A, Muriel G, Tutor P, Contreras C, Dpto. Facultad de Ciencias de la Salud. Revisión bibliográfica. Prevención del ictus. Disponible en: https://crea.ujaen.es/bitstream/10953.1/22998/1/G%C3%A1lvez_Muriel_Pilar.pdf
5. Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, et al. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Am J Cardiol. 2014 Jan. Disponible en: https://www.ajconline.org/article/S0002-9149(13)01938-3/fulltext#secsectitle0020
6. Nanau RM, Delzor F, Neuman MG. Efficacy and safety of prasugrel in acute coronary syndrome patients. Clin Biochem. 2014 May;47(7-8):516-28. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0009912014001180
Downloads
Published
Issue
Section
License
Copyright (c) 2025 María Eugenia Piesciorovsky, Claudia Sabattini Analía (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
